USA - NASDAQ:MRNA - US60770K1079 - Common Stock
ChartMill assigns a Buy % Consensus number of 55% to MRNA. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-23 | UBS | Maintains | Buy -> Buy |
| 2025-10-23 | JP Morgan | Maintains | Underweight -> Underweight |
| 2025-10-23 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-10-20 | Needham | Reiterate | Hold -> Hold |
| 2025-10-10 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-08-22 | Leerink Partners | Maintains | Underperform -> Underperform |
| 2025-08-04 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-07-22 | B of A Securities | Maintains | Underperform -> Underperform |
| 2025-05-22 | JP Morgan | Maintains | Underweight -> Underweight |
| 2025-05-02 | UBS | Maintains | Buy -> Buy |
| 2025-05-02 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2025-05-02 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-05-02 | Evercore ISI Group | Maintains | In-Line -> In-Line |
| 2025-04-09 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-03-21 | JP Morgan | Maintains | Underweight -> Underweight |
| 2025-03-13 | Citigroup | Initiate | Neutral |
| 2025-02-19 | UBS | Maintains | Buy -> Buy |
| 2025-02-18 | RBC Capital | Reiterate | Sector Perform -> Sector Perform |
| 2025-02-18 | Barclays | Downgrade | Overweight -> Equal-Weight |
| 2025-02-11 | B of A Securities | Maintains | Underperform -> Underperform |
| 2025-01-29 | Goldman Sachs | Downgrade | Buy -> Neutral |
| 2025-01-28 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-01-27 | Evercore ISI Group | Maintains | In-Line -> In-Line |
| 2025-01-15 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-01-08 | UBS | Maintains | Buy -> Buy |
| 2024-12-18 | Argus Research | Downgrade | Buy -> Hold |
| 2024-12-10 | B of A Securities | Reiterate | Underperform |
| 2024-11-26 | JP Morgan | Maintains | Underweight -> Underweight |
| 2024-11-18 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-11-18 | HSBC | Upgrade | Hold -> Buy |
30 analysts have analysed MRNA and the average price target is 47.37 USD. This implies a price increase of 74.42% is expected in the next year compared to the current price of 27.16.
The consensus rating for MODERNA INC (MRNA) is 55.3333 / 100 . This indicates that analysts generally have a neutral outlook on the stock.